STATE STREET CORP - SANGAMO THERAPEUTICS INC ownership

SANGAMO THERAPEUTICS INC's ticker is SGMO and the CUSIP is 800677106. A total of 134 filers reported holding SANGAMO THERAPEUTICS INC in Q3 2023. The put-call ratio across all filers is 1.23 and the average weighting 0.0%.

Quarter-by-quarter ownership
STATE STREET CORP ownership history of SANGAMO THERAPEUTICS INC
ValueSharesWeighting
Q3 2023$1,611,114
-53.3%
2,686,085
+1.1%
0.00%
Q2 2023$3,452,315
-78.1%
2,655,627
-70.4%
0.00%
-100.0%
Q1 2023$15,770,617
-74.3%
8,960,578
-54.2%
0.00%
-50.0%
Q4 2022$61,474,192
+80.0%
19,577,768
+181.0%
0.00%0.0%
Q3 2022$34,145,000
+6.6%
6,968,276
-10.0%
0.00%0.0%
Q2 2022$32,041,000
-29.1%
7,739,471
-0.5%
0.00%0.0%
Q1 2022$45,175,000
-2.9%
7,775,327
+25.3%
0.00%0.0%
Q4 2021$46,534,000
-12.0%
6,204,587
+5.7%
0.00%
-33.3%
Q3 2021$52,886,000
-26.3%
5,869,755
-2.1%
0.00%
-25.0%
Q2 2021$71,750,000
-12.5%
5,994,166
-8.4%
0.00%
-20.0%
Q1 2021$81,980,000
-17.6%
6,542,667
+2.6%
0.01%
-16.7%
Q4 2020$99,514,000
+49.9%
6,377,057
-9.2%
0.01%
+20.0%
Q3 2020$66,388,000
+14.2%
7,025,167
+8.3%
0.01%
+25.0%
Q2 2020$58,141,000
+88.3%
6,488,918
+33.9%
0.00%
+33.3%
Q1 2020$30,880,000
-23.4%
4,847,768
+0.7%
0.00%0.0%
Q4 2019$40,298,000
-11.3%
4,814,626
-4.1%
0.00%0.0%
Q3 2019$45,423,000
-21.1%
5,019,076
-6.1%
0.00%
-25.0%
Q2 2019$57,597,000
+3.2%
5,347,908
-8.6%
0.00%0.0%
Q1 2019$55,834,000
-17.7%
5,852,641
-1.0%
0.00%
-33.3%
Q4 2018$67,849,000
-38.5%
5,910,152
-9.3%
0.01%
-25.0%
Q3 2018$110,392,000
+27.8%
6,512,627
+7.1%
0.01%
+14.3%
Q2 2018$86,346,000
+0.2%
6,080,644
+34.0%
0.01%0.0%
Q1 2018$86,206,000
+32.1%
4,536,951
+14.0%
0.01%
+40.0%
Q4 2017$65,268,000
+50.5%
3,979,593
+37.7%
0.01%
+25.0%
Q3 2017$43,373,000
+163.8%
2,890,810
+54.7%
0.00%
+300.0%
Q2 2017$16,441,000
+156.5%
1,868,285
+51.6%
0.00%0.0%
Q1 2017$6,409,000
+77.3%
1,231,989
+3.8%
0.00%
Q4 2016$3,614,000
-67.8%
1,186,569
-51.1%
0.00%
-100.0%
Q3 2016$11,231,000
+1.7%
2,426,552
+27.2%
0.00%0.0%
Q2 2016$11,042,000
-18.9%
1,906,940
-15.3%
0.00%0.0%
Q1 2016$13,622,000
-19.6%
2,251,763
+21.4%
0.00%
-50.0%
Q4 2015$16,934,000
-29.0%
1,854,666
-56.1%
0.00%
-33.3%
Q3 2015$23,853,000
-36.8%
4,229,198
+24.4%
0.00%
-25.0%
Q2 2015$37,720,000
-4.4%
3,400,985
+35.1%
0.00%0.0%
Q1 2015$39,472,000
+11.5%
2,517,383
+8.2%
0.00%0.0%
Q4 2014$35,404,000
+29.6%
2,327,109
-8.1%
0.00%
+33.3%
Q3 2014$27,318,000
-15.6%
2,533,186
+19.5%
0.00%0.0%
Q2 2014$32,379,000
-5.8%
2,120,350
+11.5%
0.00%
-25.0%
Q1 2014$34,378,000
-7.1%
1,901,499
-40.2%
0.00%
+100.0%
Q4 2013$37,016,000
+63.6%
3,180,142
+47.3%
0.00%
-33.3%
Q3 2013$22,623,000
+6.5%
2,158,797
-20.6%
0.00%0.0%
Q2 2013$21,245,0002,720,0260.00%
Other shareholders
SANGAMO THERAPEUTICS INC shareholders Q3 2023
NameSharesValueWeighting ↓
RA Capital Management 6,000,000$66,540,0006.69%
FIC CAPITAL INC 787,529$8,734,0003.47%
RA Capital Management 1,220,209$13,532,0001.36%
PRINCETON CAPITAL MANAGEMENT INC 114,120$1,266,0000.67%
Perceptive Advisors 800,000$8,872,0000.53%
Cormorant Asset Management, LP 361,000$4,003,0000.53%
Highlander Capital Management, LLC 43,500$482,0000.43%
APEX CAPITAL, LLC 439,900$4,878,0000.42%
WASATCH ADVISORS LP 3,091,386$34,283,0000.37%
Baker Brothers Advisors 3,230,932$35,831,0000.31%
View complete list of SANGAMO THERAPEUTICS INC shareholders